NP2 COST ASSOCIATED WITH PERSISTENCY AMONG PATIENTS WITH PARTIAL SEIZURE DISORDER SWITCHING TO OXCARBAZEPINE MONOTHERAPY  by Lee, WC et al.
652 Abstracts
tion were located in Europe (N = 19), followed by Asia (N = 9),
North America (N = 7), and Oceania (N = 6). More research is
needed to determine the extent of PE education from other
sources (e.g. other disciplines and non-university based).
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Prior to patent expiry of a drug, the manufacturer will generally
increase marketing efforts in order to maintain market-share.
The introduction of generics will lead to strong competition,
forcing the original patent holder to change their marketing
strategy. These effects, together with other factors (e.g. govern-
mental price legislation) may lead to increasing drug expendi-
tures. In order to increase price competition the Dutch
government plans to modernize the drug reimbursement system,
which is conceived to inadequately control drug prices. In par-
ticular, drug prices may not relevantly decrease due to lack of
incentives for price competition. OBJECTIVES: To investigate
the magnitude of effects on market-share and drug prices, we
evaluated trends in drug volume and costs after patent expiry for
enalapril, ﬂuoxetine and ranitidine in the The Netherlands.
METHODS: Governmental price, volume and reimbursement
policies were evaluated in order to provide a framework for
developments after patent expiry. Drug use was measured as
Deﬁned Daily Doses (DDD) per 1000 population, derived from
the InterAction DataBase, comprising pharmacies in the North
of the The Netherlands. Drug costs were calculated per DDD.
Estimated trendlines for drug costs and share of drugs in the dif-
ferent trade-channels (specialité, parallel, generic) were com-
pared. RESULTS: After the patent expired, costs per DDD—for
enalapril, ﬂuoxetine and ranitidine—decreased with 61%, 51%
and 69% respectively. For enalapril and ﬂuoxetine statistical sig-
niﬁcant differences in trendlines were found. For all investigated
drugs, generic products rapidly took over the majority of the
market-share (over 75%). Nearly all new users received a generic
drug after patent expiry. Further results will be presented on
omeprazol and simvastatine, with very recent patent expiries.
CONCLUSIONS: Our ﬁndings indicate that patent expiry may
cause price competition leading to cost decreases. This is oppo-
site the current opinion that the drug reimbursement system
would inadequately control drug prices.
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OBJECTIVES: To assess the health related quality of life in
common neuromuscular disease. METHODS: The health related
quality of life (HrQol) of 73 patients (mean age: 54.0 ± 16.9;
w/m: 41 :32) with Amyotrophic Lateral Sclerosis (ALS, n = 25),
Myasthenia Gravis (MSG, n = 32) or Facioscapulohumeral Mus-
cular Dystrophy (FSHD, n = 16) has been assessed using the SF-
36 and the EQ-5D. RESULTS: Measuring the HrQol using the
EQ-5D for the three diseases the overall score differs slightly
depending on sex (female 0.79 ± 0.22, male 0.66 ± 0.29). In con-
trast the disease speciﬁc overall score for patients with ALS was
0.53 ± 0.28, with FSHD 0.78 ± 0.13 and for patients with MSG
0.87 ± 0.19. This distribution was also true for the VAS (ALS
37.5 ± 13.59 FSHD 59.06 ± 17.91, MSG 65.63 ± 24.02). The
results of the SF 36 (n = 72) subscale bodily pain and mental
health for the three subgroups were not different. Differences
were found for the subscales physical function (ALS 41 ± 31,
FSHD 45 ± 35, MSG 72 ± 29), role limitations due to physical
problems (ALS 2 ± 7, FSHD 40 ± 43, MSG 49 ± 51), general
health perceptions (ALS 31 ± 14, FSHD 52 ± 21, MSG 39 ± 49),
vitality (ALS 37 ± 15, FSHD 52 ± 21, MSG 44 ± 44), social func-
tioning (ALS 56 ± 29, FSHD 82 ± 16, MSG 81 ± 25) and role
limitations due to emotional problems (ALS 24 ± 60, FSHD 81
± 34, MSG 65 ± 58). The results that the physical functioning
of the ALS and FSHD patients are similar, but the general health
perception of the FSHD patients needs further evaluation. An
additional aspect is the strong role limitation due to emotional
problems of ALS patients. CONCLUSIONS: Neuromuscular
diseases have a considerable impact on health-related quality of
life. Patients with ALS and FSHD have diminished scores in the
EQ-5D overall score and in the VAS. The SF-36 reﬂects in more
detail the inﬂuence of the three diseases on the different dimen-
sions of health-related quality of life.
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OBJECTIVES: Patients refractory to initial anti epileptic drugs
(AEDs) monotherapy may undergo a change in their therapeu-
tic regimen. This study sought to compare the economic costs of
care of patients refractory to initial AED therapy that was not
oxcarbazepine (Trileptal®), who were switched to oxcar-
bazepine (OXC) monotherapy and who stayed on OXC for an
entire 12 months follow-up (Cohort A), compared with the costs
of the patients who failed to be on the same therapy within one
year (Cohort B). METHODS: Retrospective data from the Phar-
Metrics integrated medical and pharmacy claims database,
which includes 57 managed care plans, were analyzed. Adult
patients receiving treatment with AEDs between January 1, 2000
and March 30, 2002 were studied. Data were analyzed from 6
months prior to treatment failure with either carbamazepine,
phenytoin, or valproic acid, and through a post-therapy period
deﬁned as 12 months after switching to OXC monotherapy.
RESULTS: 169 adult patients were observed. 31.4% (53/169)
patients stayed on OXC for an entire year of follow-up, consti-
tuting Cohort A. 116 patients (Cohort B) either switched to
another drug or opted for a combination therapy at some point
within one year. Demographic and clinical characteristics were
statistically similar between cohorts. Although pre-index treat-
ment costs are similar between the two cohorts ($9434 +SD
$14,512 versus $9430 + $15,229), the mean cost of care in
Cohort A decreased by $1123 while the mean cost rose for
Cohort B during the post-failure period (p < 0.01). Post-failure
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costs for cohort B were substantially higher than for cohort A
($8312 + $11,218, versus ($11,760 + $18,155, p = 0.03). CON-
CLUSIONS: The persistent use of OXC provided a less costly
alternative for managed care organizations among patients
switched to OXC after initial monotherapy failure. This study
ﬁnding encourages the clinical practitioner to promote patients’
persistency on the OXC monotherapy when medically appro-
priate.
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OBJECTIVES: According to current guidelines, there is no hier-
archy between antiepileptic drugs (AED), and the choice should
take into account efﬁcacy, tolerability, pharmacokinetic proper-
ties, impact on quality of life, patient preference and cost. Older
AEDs such as carbamazepine and valproate are often prescribed,
with cost constraints cited as reason for the treatment choice.
Given the relative scarcity of long term comparative trials, eco-
nomic modelling is appropriate to assess whether lower drug
costs justify the use of older AEDs. METHODS: A Markov
model was developed to capture long-term outcomes (1–15
years) of treatment strategies (ﬁrst- and second-line monothera-
pies). Expected treatment costs (routine medical costs, adverse
event costs, and drug costs) were calculated by disease severity
for 2004 from the perspective of a third party payer. Results of
a discrete choice experiment exploring whether people with
epilepsy were willing to trade months of life against improve-
ments in seizure control and side effects were used to calculate
expected utilities. A range of relevant sensitivity analyses were
undertaken. RESULTS: At one year, treatment with only older
AEDs was least costly, but also resulted in the lowest QALY
gains. Both the use of topiramate instead of an older AED as
second-line, or instead of an older AED as ﬁrst-line were asso-
ciated with incremental cost-effectiveness ratios (ICER) between
20,000€ and 30,000€/QALY gained. At longer time horizons
both the ICER of offering topiramate second-line, and the ICER
of offering topiramate ﬁrst-line gradually improved. CONCLU-
SIONS: Topiramate either as ﬁrst- or second-line monotherapy
delivers extra health beneﬁts for a slight and acceptable increase
in costs, showing that topiramate treatment is cost-effective. The
decreasing ICERs over time show the importance of longer treat-
ment retention. Choice of AED should therefore be based on
patient-speciﬁc criteria only.
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OBJECTIVES: To prospectively evaluate the health economic
burden of patients with Parkinson’s disease (PD) in Germany
over a 12-months observation period. METHODS: Direct and
indirect costs were evaluated in 145 patients with PD (mean age:
67.3 ± 9.6 years) in Germany. Clinical evaluations were per-
formed at baseline, 3, 6 and 12 months. Relevant economic data
were documented in a special patient diary over the 12-month
period. Costs (2002€) were derived from various German
medical economic resources. Costs were calculated from the per-
spective of health insurance (Gesetzliche Krankenkassse, GKV),
transfer payment providers and the individual patient. Costs are
presented as means ± standard deviation (SD). RESULTS: We
estimated per patient direct, indirect, and total costs for the
twelve-month period. The costs from the perspective of the
health insurance GKV consist of direct medical costs 3770 ±
7020€; including rehabilitation (1080 ± 3320€), hospitalization
(2200 ± 5590€), outpatient treatment (80 ± 50€), non-medical
treatment (390 ± 580€) and ambulatory diagnostic procedures
(20 ± 40€). In addition, drug costs for anti-parkinsonian treat-
ment were 3350 ± 2720€. Non-medical direct costs calculated
from the GKV perspective were estimated to be 1040 ± 3350€,
which included transportation (30 ± 50€), special equipment
(880 ± 3100€), social services (30 ± 310€), and sickness beneﬁt
(110 ± 1330€). The total medical (including drug costs) and 
non-medical direct costs for the GKV were 8160 ± 8770€
and depends on disease severity and the occurrence of motor 
complications. For the nursing insurance payments of 2990 ±
6590€ were calculated, for the retirement insurance 1410 ±
3210€, and patient and caregiver costs of 3150 ± 5320€. Total
indirect costs amounted to 6590 ± 13,150€. On average, a total
of 22,400 ± 25,410€ per patient were attributable to PD. CON-
CLUSION: The result of the study clariﬁes the high ﬁnancial
burden of PD on society and patients. This underscores the need
for further economic and medical research to optimize treatment
for PD.
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To feel personally concerned with a risk, one needs to experience
it. OBJECTIVES: The ICARE programme’s objective is to asses
patients’ knowledge of the consequences of sun exposure.
METHODS: Every patient coming to an outpatient pharmacy in
order to obtain advice or treatment following a sunburn was
remitted a questionnaire assessing their knowledge of the conse-
quences of sun exposure. RESULTS: Men and women act dif-
ferently towards sun exposure. If 41% expose themselves more
than 2 hours per day (W 40%, M 43%) and if more than 50%
expose themselves between 11h00 and 16h00, then more than
70% do it after 16h00. The only difference concerns sun expo-
sure before 11h00, for which 35% of women and only 19% of
men are concerned (p = 0.03). Concerning sun protection with
protective skin lotions, 59% of women report applying them reg-
ularly vs. 33% of men (p = 0.003). The back and arms are the
most often expressed localisation sunburns for women (50% and
43%) vs. the back and face for men (52% and 38%). Eight
percent (8%) admitted that their sunburn messed their vacation
up, 38% reported sleep disturbance and 26% couldn’t do what
they wanted because of their sunburn. Assessment of QoL using
the DLQI showed evidence of quality of life impairment stronger
for women than for men, mean scores being respectively 4.89
and 2.72 (p < 0.05). CONCLUSIONS: The results of our study
are similar to the one of McCarthy et al where men exhibited a
signiﬁcantly higher frequency of sunburn, employed fewer sun-
protective measures, and demonstrated less knowledge concern-
ing sun safety information and skin cancer than women. The
direct consequence of this is a profound impairment of quality
